

***Fiscal Year 2022 Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-22-DMDRP-IDA</p>	<p><i>Established Investigators:</i> Independent investigators at or above the level of Assistant Professor (or equivalent); <i>or</i></p> <p><i>New Investigator – Early Stage:</i> Investigators that meet the following criteria by the application submission deadline date:</p> <ul style="list-style-type: none"> • Have not previously received a DMDRP Idea Development Award • Are within 10 years of first faculty appointment (or equivalent) <p><i>New Investigator – Transitioning:</i> Established investigators in an area other than muscular dystrophy at or above the level of Assistant Professor (or equivalent) seeking to transition to a career in Duchenne muscular dystrophy (DMD), thereby bringing their expertise to the field.</p> <ul style="list-style-type: none"> • Must pursue an active line of research in DMD and commit at least 10% of their efforts during each budget year toward the proposed DMD research project 	<ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes. • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Therapies that will be efficacious across the lifespan, particularly in adolescents and adults are encouraged. • Preliminary data are required. • Clinical trials or applications including a clinical trial aim are not allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): August 3, 2022 5:00 p.m. Eastern time (ET)</p> <p>Application: November 15, 2022 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-22-DMDRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p> <p>Early-Career Partnering Principal Investigator (PI) Option:</p> <ul style="list-style-type: none"> • The Partnering PI must be an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application. • It is encouraged, but not required, that the partnering PI is a clinician or clinical scientist (M.D. or M.D./Ph.D.) to increase collaboration between clinical and non-clinical aspects of DMD research. 	<ul style="list-style-type: none"> • Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic. • Research projects investigating therapies that will be efficacious across the lifespan, particularly in adolescents and adults are strongly encouraged. • Preliminary data are required. • Clinical trials are allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,250,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. <p>Early-Career Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,350,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): August 3, 2022 5:00 p.m. ET</p> <p>Application: November 15, 2022 11:59 p.m. ET</p>